| __timestamp | BioCryst Pharmaceuticals, Inc. | Viking Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 7461000 | 1244910 |
| Thursday, January 1, 2015 | 13047000 | 5029636 |
| Friday, January 1, 2016 | 11253000 | 4846776 |
| Sunday, January 1, 2017 | 13933000 | 5329003 |
| Monday, January 1, 2018 | 29514000 | 7121000 |
| Tuesday, January 1, 2019 | 37121000 | 9128000 |
| Wednesday, January 1, 2020 | 67929000 | 10731000 |
| Friday, January 1, 2021 | 118818000 | 10701000 |
| Saturday, January 1, 2022 | 159371000 | 16121000 |
| Sunday, January 1, 2023 | 213894000 | 37021000 |
Igniting the spark of knowledge
In the competitive world of biotechnology, managing operational costs is crucial for success. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Viking Therapeutics, Inc. and BioCryst Pharmaceuticals, Inc. over the past decade. From 2014 to 2023, BioCryst Pharmaceuticals saw a staggering 2,765% increase in SG&A expenses, peaking at $213.9 million in 2023. In contrast, Viking Therapeutics experienced a more modest rise of 2,872%, reaching $37 million in the same year.
BioCryst's expenses surged significantly post-2020, reflecting strategic investments or expansions. Meanwhile, Viking's steady growth suggests a more controlled approach to scaling operations. Understanding these trends can offer investors insights into each company's operational strategies and financial health. As the biotech industry continues to evolve, monitoring SG&A efficiency remains a vital metric for assessing corporate performance.
Who Optimizes SG&A Costs Better? AstraZeneca PLC or BioCryst Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Sanofi or Viking Therapeutics, Inc.
Bristol-Myers Squibb Company or BioCryst Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Gilead Sciences, Inc. and Viking Therapeutics, Inc.
Incyte Corporation and Viking Therapeutics, Inc.: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Apellis Pharmaceuticals, Inc. or Viking Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Viking Therapeutics, Inc. and MorphoSys AG
Cost Management Insights: SG&A Expenses for Viking Therapeutics, Inc. and Supernus Pharmaceuticals, Inc.
Viking Therapeutics, Inc. and Evotec SE: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Rhythm Pharmaceuticals, Inc. vs BioCryst Pharmaceuticals, Inc.
Comparing SG&A Expenses: Perrigo Company plc vs BioCryst Pharmaceuticals, Inc. Trends and Insights
Selling, General, and Administrative Costs: Galapagos NV vs BioCryst Pharmaceuticals, Inc.